GlassScriptPhysician profile
Byron D Baptist
NPI 1518253699
$2,807.94
in general payments reported to CMS, 2019-2025
30 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $718 · 2022: $23.14 · 2023: $164 · 2024: $140 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.58 |
| Education | $115.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $353.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $246.00 | 2019-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $236.38 | 2019-2022 | |
| Astellas Pharma US INC | $220.33 | 2019-2020 | |
| Allergan, INC. | $186.75 | 2019-2020 | |
| Lilly USA, LLC | $181.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $137.11 | 2019-2020 | |
| Lundbeck LLC | $115.62 | 2025 | Rexulti |
| Amgen INC. | $110.45 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $99.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $95.43 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $84.01 | 2019-2020 | |
| Abbvie INC. | $76.25 | 2019-2025 | |
| Exact Sciences Corporation | $72.21 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $71.22 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.93 | 2019-2023 | Farxiga |
| Abbott Laboratories | $68.41 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.86 | 2019 | |
| Sumitomo Pharma America, INC. | $60.29 | 2023-2025 | Gemtesa |
| Scilex Pharmaceuticals INC. | $44.22 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $39.45 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $28.76 | 2019 | |
| Daiichi Sankyo INC. | $26.09 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $25.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $16.83 | 2025 | Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $16.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.92 | 2025 | Strensiq |
| Nalpropion Pharmaceuticals LLC | $13.45 | 2019 | |
| Antares Pharma, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Baptist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.